Category: Immunosuppressive

Daclizumab Overview

Daclizumab (trade name Zinbryta, by Biogen) is a therapeutic humanized monoclonal antibody used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. It was formerly marketed under the trade name Zenapax to prevent acute rejection in people with kidney transplants along with cyclosporine and corticosteroids but marketing of the drug for that purpose was discontinued in 2009 due to la...

Read more Daclizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daclizumab

Recent Daclizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 150mg/ml, 5mg/ml
  • Vial: 25mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Daclizumab: (1 result)

Sorted by National Drug Code
  • 0074-0034 Zinbryta 150 mg/ml Subcutaneous Injection, Solution by Abbvie

Other drugs which contain Daclizumab or a similar ingredient: (2 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 October 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.